1873 — VIVA Biotech Holdings Share Price
- HK$3.09bn
- HK$3.47bn
- CNY1.99bn
- 83
- 59
- 94
- 93
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.78 | ||
Price to Tang. Book | 2.32 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.49 | ||
EV to EBITDA | 6.92 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 5.9% | ||
Return on Equity | 4.47% | ||
Operating Margin | 17.6% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 696.96 | 2,104.08 | 2,379.63 | 2,155.58 | 1,986.65 | 3,396.18 | 2,295,246.46 | 43.8% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | +246.3 | +298.89 | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
VIVA Biotech Holdings is an investment holding company. The Company has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The Company conducts business primarily in the United States, China, Europe and other regions.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 27th, 2008
- Public Since
- May 9th, 2019
- No. of Employees
- 2,063
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 2,131,775,305

- Address
- 735 Ziping Road, Shanghai, 201318
- Web
- https://www.vivabiotech.com/
- Phone
- +86 2160893288
- Auditors
- Ernst & Young
Upcoming Events for 1873
Similar to 1873
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 24:01 UTC, shares in VIVA Biotech Holdings are trading at HK$1.48. This share price information is delayed by 15 minutes.
Shares in VIVA Biotech Holdings last closed at HK$1.48 and the price had moved by +164.29% over the past 365 days. In terms of relative price strength the VIVA Biotech Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +167.3% over the past year.
The overall consensus recommendation for VIVA Biotech Holdings is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVIVA Biotech Holdings does not currently pay a dividend.
VIVA Biotech Holdings does not currently pay a dividend.
VIVA Biotech Holdings does not currently pay a dividend.
To buy shares in VIVA Biotech Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$1.48, shares in VIVA Biotech Holdings had a market capitalisation of HK$3.09bn.
Here are the trading details for VIVA Biotech Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1873
Based on an overall assessment of its quality, value and momentum VIVA Biotech Holdings is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in VIVA Biotech Holdings is HK$7.96. That is 437.56% above the last closing price of HK$1.48.
Analysts covering VIVA Biotech Holdings currently have a consensus Earnings Per Share (EPS) forecast of CNY0.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like VIVA Biotech Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +66.83%.
As of the last closing price of HK$1.48, shares in VIVA Biotech Holdings were trading +57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The VIVA Biotech Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on VIVA Biotech Holdings' directors